Biogen Halves Aduhelm Price, Readies $500m In Cost Cuts
Potential Job Losses Loom As Holidays Approach
Executive Summary
The Alzheimer’s drug’s price was cut to $28,200 per year just one month before CMS is expected to issue a draft national coverage determination for amyloid-clearing antibodies, raising questions about the timing.
You may also be interested in...
J.P. Morgan Day Three: 2023 Is A Year Of Commercial Challenges
Daily notebook from the J.P. Morgan Healthcare Conference: Gene therapy Vertex enters pricing negotiations on gene therapy, Sanofi sees opportunity in hemophilia despite new gene therapy, and AbbVie raises guidance ahead of the introduction of Humira biosimilars. Plus ICER's Steven Pearson and former Biogen CEO George Scangos weigh in on Alzheimer's developments.
Eisai/Biogen’s Leqembi Will Launch Below Aduhelm At $26,500 Per Year
With accelerated approval granted and a supplemental filing for full approval in the FDA's hands, Eisai set a price it says is below the “societal value” its Alzheimer’s drug provides as it prepares to seek Medicare coverage. Labeling notably comes with no black box warning or safety restrictions despite various concerns.
ICER Sets Ceiling For Anti-Amyloid Pricing; Will Eisai And Lilly Raise The Roof?
The independent drug pricing watchdog said lecanemab and donanemab would be cost-effective at $8,500-$20,600 per year, but pricing has been expected to be closer to Aduhelm’s $28,200 price tag.